USFDA Issues Warning Letter to Dabur Over Manufacturing and Data Integrity Lapses
The US Food and Drug Administration (USFDA) issued a warning letter to Dabur India regarding significant violations of current good manufacturing practices at its Silvassa pharmaceutical facility. The regulator identified data integrity issues, inadequate quality controls, incomplete laboratory records, and falsification of an equipment usage logbook. These lapses led to the products being considered "adulterated" under US law, prompting an import alert on items from the plant. Dabur's CEO Mohit Malhotra was formally notified of these concerns.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is negative (30/100). Lens Score 66/100.
Outlets measured: freepressjournal, businessstandard. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (28–32/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
businessstandard broke this story on 5 Aug, 05:26 pm. Other outlets followed.